REPLIMUNE GROUP INC (REPL)

US76029N1063 - Common Stock

8.22  -0.03 (-0.36%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

REPLIMUNE GROUP INC

NASDAQ:REPL (3/28/2024, 9:49:09 AM)

8.22

-0.03 (-0.36%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap504.63M
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

REPL Daily chart

Company Profile

Replimune Group, Inc. is a clinical-stage biotechnology company. The company is headquartered in Woburn, Massachusetts and currently employs 284 full-time employees. The company went IPO on 2018-07-20. The firm is advancing a pipeline of tumor-directed oncolytic immunotherapies derived from its RPx platform to fill unmet need across cancer types. The firm's lead product candidate, RP1, is a selectively replicating version of HSV-1 that expresses GALV-GP R and human GM-CSF. RP1 is designed to treat more immune responsive tumor types. The firm's pipeline product candidates include RP2 and RP3. The encoded GALV-GP R protein enhances the tumor killing ability of the virus and increases immunogenic cell death. RP2 is an additionally encodes an anti-CTLA-4 antibody has designed to treat more immunologically silent tumors. RP3 expresses a pair of immune costimulatory pathways activating ligands, CD40L and 4-1BBL, to further increase the potency of the immune responses to treat immunologically cold tumors.

Company Info

REPLIMUNE GROUP INC

500 Unicorn Park Dr

Woburn MASSACHUSETTS 01801

P: 17812229600

CEO: Philip Astley-Sparke

Employees: 284

Website: https://www.replimune.com/

REPL News

News Image2 days ago - Replimune Group IncReplimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitions

Philip Astley-Sparke to transition from current role of CEO to Executive Chairman Planned leadership changes position the Company for commercialization ...

News Image2 months ago - Seeking AlphaReplimune Group GAAP EPS of -$0.77 beats by $0.16 (NASDAQ:REPL)

Replimune Group reported Q3 2024 financial results, beating expectations with a GAAP EPS of -$0.77.

News Image2 months ago - Replimune Group IncReplimune Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update

Positive data update in December 2023 for all 140 patients in the IGNYTE clinical trial cohort of RP1 in anti-PD1 failed melanoma demonstrating durability...

News Image2 months ago - DISCO PharmaceuticalsDISCO Pharmaceuticals launches as the surfaceome company with EUR 20 Million in Seed Financing

Transformative surfaceome discovery technology enables a comprehensive map of the cancer cell surface to identify a multitude of novel druggable targets....

News Image3 months ago - Replimune Group IncReplimune to Present at the 42nd Annual J.P. Morgan Healthcare Conference

WOBURN, Mass., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development...

News Image3 months ago - Market News VideoCommit To Buy Replimune Group At $7.50, Earn 31.3% Annualized Using Options

REPL Twits

Here you can normally see the latest stock twits on REPL, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example